Survey of treatment strategy and analysis of prognostic factors in borderline resectable pancreatic cancer
Not Applicable
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000021799
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
Unsuitable case in this study
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method disease-free survival, neoadjuvant theraphy methods, completion rates of neoadjuvant theraphy, RECIST, CA19-9, SUVmax, Pathological effect, R0 resection rate, postoperative complications, postoperative diarrhea rate, readmission rate, completion rates of adjuvant theraphy, the administration period of adjuvant chemotherapy, patterns of recurrence
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways (e.g., KRAS, TGF-β) influence prognosis in borderline resectable pancreatic cancer per JPRN-UMIN000021799 meta-analysis?
How do neoadjuvant chemotherapy regimens (e.g., FOLFIRINOX, gemcitabine/nab-paclitaxel) compare in borderline resectable pancreatic cancer outcomes?
Which biomarkers (e.g., CA19-9, PD-L1 expression) predict survival in JPRN-UMIN000021799 pancreatic cancer prognostic analysis?
What adverse event profiles are associated with neoadjuvant therapies for borderline resectable pancreatic cancer in clinical surveys?
How do PD-1/PD-L1 inhibitors combined with chemotherapy impact resectability rates in borderline pancreatic cancer trials?